Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
9.46 USD | -1.97% | +0.93% | -42.99% |
14/05 | Neumora Therapeutics Begins Phase 2 Study of Navacaprant in Bipolar Depression | MT |
14/05 | Neumora Therapeutics, Inc. Announces Initiation of Phase 2 Study of Navacaprant in Bipolar Depression | CI |
- Stock Market
- Equities
- NMRA Stock
- News Neumora Therapeutics, Inc.